Rochester, NY 6/11/2009 11:43:42 PM
NASDAQ Afternoon Movers - sourced by WhisperFromWallStreet.com - Corel Corporation,CREL - Human Genome Sciences, Inc.,HGSI - American Capital, Ltd.,ACAS
Corel Corporation - Human Genome Sciences, Inc. - American Capital, Ltd.
NASDAQ Afternoon Movers - sourced by WhisperFromWallStreet.com - Corel Corporation,CREL - Human Genome Sciences, Inc.,HGSI - American Capital, Ltd.,ACAS
Corel Corporation,CREL
Corel Corporation operates as a packaged software company offering products for the graphics and productivity, and digital media markets worldwide. Its graphics and productivity products include CorelDRAW Graphics Suite, a page layout, image editing, and bitmap conversion software suite; Corel Painter, a digital painting and drawing software; CorelDESIGNER Technical Suite, a graphics application for creating or updating technical illustrations; WinZip, a compression utility that reduces the size of computer files for transmission and storage purposes; iGrafx Flowcharter products, which allow enterprises to analyze and streamline business processes; and WordPerfect Office, a software application that features Microsoft compatible word processing, spreadsheet, database, and e-mail, calendaring, and contact management applications.
Last Trade: 3.92
Day's Range: 3.02 - 4.27
52wk Range: 1.35 - 11.39
Volume: 104,003
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Human Genome Sciences, Inc.,HGSI
Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes.
Last Trade: 3.33
Day's Range: 3.08 - 3.48
52wk Range: 0.45 - 8.00
Volume: 19,787,384
---
American Capital, Ltd.,ACAS
Struggling private equity firm American Capital Ltd declared a dividend of $1.07 a share in order to maintain its tax status as a regulated investment company and eliminate its income tax liability.
Shares of the company surged 22 percent to $3.37 in morning trade on Nasdaq.
ABOUT
American Capital, Ltd., formerly known as American Capital Strategies, Ltd., is a principal investment firm specializing in management and employee private equity buyouts, acquisitions, recapitalizations, mergers and acquisition, add-on acquisitions, securitizations, special situations, growth capital investments in middle market companies, early stage in mature private and public companies, corporate divestitures, acquisitions of portfolio companies of private equity firms, acquisitions of family-owned or closely held businesses, change of control, or the exit of minority shareholders, going private transactions, and ownership transitions.
Last Trade: 3.35
Day's Range: 2.72 - 3.47
52wk Range: 0.58 - 30.38
Volume: 14,266,378
---
Investors in today's market need to use every tool available to stay ahead of the trends. WhisperfromWallstreet.com can be one of your primary tools. Every day we send free stock alerts to our subscribers, these alerts are for stocks we feel will shortly begin a significant move. To date in 2009 we have sent over 36 stock alerts to our subscribers with an average price gain of 88%. To be notified of these stock alerts please visit our site and sign up for our free alerts. You can then track our results and test our accuracy.
Sign up for our FREE alerts at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
